CARTT

Type: Concept

As of November 2026, CARTT has been mentioned in one podcast episode on Kaggle (Aug 2025). Mentioned as a treatment option and its comparison with bone marrow transplants in leukemia cases.

Chimeric antigen receptor T cells —also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor.